Evidence map›Paper›PMID 38158001›Full record

ArticleVascular pharmacology2024

Prime editing in mice with an engineered pegRNA.

Amr R Salem, W Bart Bryant, Jaser Doja, Susan H Griffin, Xiaofan Shi, Weihong Han, Yunchao Su, Alexander D Verin, Joseph M Miano

Open access · greenAbstract read
In one paragraph

Article in Vascular pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Amr R SalemVascular Biology Center, Medical College of Georgia at Augusta University, Augusta, GA 30912, United States of America. Electronic address: asalem@augusta.edu.
W Bart BryantVascular Biology Center, Medical College of Georgia at Augusta University, Augusta, GA 30912, United States of America.
Jaser DojaVascular Biology Center, Medical College of Georgia at Augusta University, Augusta, GA 30912, United States of America.
Susan H GriffinVascular Biology Center, Medical College of Georgia at Augusta University, Augusta, GA 30912, United States of America.
Xiaofan ShiDepartment of Pharmacology and Toxicology, Medical College of Georgia at Augusta University, Augusta, GA 30912, United States of America.
Weihong HanDepartment of Pharmacology and Toxicology, Medical College of Georgia at Augusta University, Augusta, GA 30912, United States of America.
Yunchao SuDepartment of Pharmacology and Toxicology, Medical College of Georgia at Augusta University, Augusta, GA 30912, United States of America.
Alexander D VerinVascular Biology Center, Medical College of Georgia at Augusta University, Augusta, GA 30912, United States of America.
Joseph M MianoVascular Biology Center, Medical College of Georgia at Augusta University, Augusta, GA 30912, United States of America.
Augusta University · US

Funding

Calpain/talin/MLCP axis in pulmonary endothelial barrier regulationR01HL158909 · NHLBI · AUGUSTA UNIVERSITY · PI SU, YUNCHAO, VERIN, ALEXANDER D · 2022 to 2025
$2.9M
HDAC9 nuclear/cytoplasmic shuttling in pulmonary vascular endothelial barrier regulationR01HL157440 · NHLBI · AUGUSTA UNIVERSITY · PI VERIN, ALEXANDER D · 2022 to 2025
$1.5M
Function and Regulation of MEIS1 in Vascular DiseaseK99HL169827 · NHLBI · AUGUSTA UNIVERSITY · PI SALEM, AMR · 2023 to 2024
$227k
BLRD VA I01 BX005350NHLBI NIH HHS K99 HL169827NHLBI NIH HHS R01 HL157440NHLBI NIH HHS R01 HL158909
6 · The paper itself

Abstract

CRISPR editing involves double-strand breaks in DNA with attending insertions/deletions (indels) that may result in embryonic lethality in mice. The prime editing (PE) platform uses a prime editing guide RNA (pegRNA) and a Cas9 nickase fused to a modified reverse transcriptase to precisely introduce nucleotide substitutions or small indels without the unintended editing associated with DNA double-strand breaks. Recently, engineered pegRNAs (epegRNAs), with a 3'-extension that shields the primer-binding site of the pegRNA from nucleolytic attack, demonstrated superior activity over conventional pegRNAs in cultured cells. Here, we show the inability of three-component CRISPR or conventional PE to incorporate a nonsynonymous substitution in the Capn2 gene, expected to disrupt a phosphorylation site (S50A) in CAPN2. In contrast, an epegRNA with the same protospacer correctly installed the desired edit in two founder mice, as evidenced by robust genotyping assays for the detection of subtle nucleotide substitutions. Long-read sequencing demonstrated sequence fidelity around the edited site as well as top-ranked distal off-target sites. Western blotting and histological analysis of lipopolysaccharide-treated lung tissue revealed a decrease in phosphorylation of CAPN2 and notable alleviation of inflammation, respectively. These results demonstrate the first successful use of an epegRNA for germline transmission in an animal model and provide a solution to targeting essential developmental genes that otherwise may be challenging to edit.

Indexed as

CRISPR-Cas SystemsGene EditingAnimalsDNAMiceNucleotidesRNA, Guide, CRISPR-Cas SystemsDNANucleotidesRNA, Guide, CRISPR-Cas SystemsCAPN2CRISPRMicePrime editing

Identifiers

PMID38158001
PMCPMC10939748
OpenAlexW4390278098

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.